Vollmer J - Search Results

1

Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.

Vollmer J, Krieg AM. Vollmer J, et al. Adv Drug Deliv Rev. 2009 Mar 28;61(3):195-204. doi: 10.1016/j.addr.2008.12.008. Epub 2009 Jan 13. Adv Drug Deliv Rev. 2009. PMID: 19211030 Review.

2

Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes.

Vollmer J, Janosch A, Laucht M, Ballas ZK, Schetter C, Krieg AM. Vollmer J, et al. Antisense Nucleic Acid Drug Dev. 2002 Jun;12(3):165-75. doi: 10.1089/108729002760220761. Antisense Nucleic Acid Drug Dev. 2002. PMID: 12162699

3

Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.

Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, Wader T, Tluk S, Liu M, Davis HL, Krieg AM. Vollmer J, et al. Eur J Immunol. 2004 Jan;34(1):251-62. doi: 10.1002/eji.200324032. Eur J Immunol. 2004. PMID: 14971051 Free article.

4

Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA).

Vollmer J, Jepsen JS, Uhlmann E, Schetter C, Jurk M, Wader T, Wüllner M, Krieg AM. Vollmer J, et al. Oligonucleotides. 2004 Spring;14(1):23-31. doi: 10.1089/154545704322988021. Oligonucleotides. 2004. PMID: 15104893

5

Immunopharmacology of CpG oligodeoxynucleotides and ribavirin.

Vollmer J, Rankin R, Hartmann H, Jurk M, Samulowitz U, Wader T, Janosch A, Schetter C, Krieg AM. Vollmer J, et al. Antimicrob Agents Chemother. 2004 Jun;48(6):2314-7. doi: 10.1128/AAC.48.6.2314-2317.2004. Antimicrob Agents Chemother. 2004. PMID: 15155243 Free PMC article.

6

Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.

Vollmer J, Weeratna RD, Jurk M, Davis HL, Schetter C, Wüllner M, Wader T, Liu M, Kritzler A, Krieg AM. Vollmer J, et al. J Leukoc Biol. 2004 Sep;76(3):585-93. doi: 10.1189/jlb.0104034. Epub 2004 Jun 24. J Leukoc Biol. 2004. PMID: 15218053

7

CpG oligodeoxynucleotides stimulate IFN-gamma-inducible protein-10 production in human B cells.

Vollmer J, Jurk M, Samulowitz U, Lipford G, Forsbach A, Wüllner M, Tluk S, Hartmann H, Kritzler A, Müller C, Schetter C, Krieg AM. Vollmer J, et al. J Endotoxin Res. 2004;10(6):431-8. doi: 10.1179/096805104225006534. J Endotoxin Res. 2004. PMID: 15588427

8

Structure-activity relationship studies on the immune stimulatory effects of base-modified CpG toll-like receptor 9 agonists.

Jurk M, Kritzler A, Debelak H, Vollmer J, Krieg AM, Uhlmann E. Jurk M, et al. Among authors: vollmer j. ChemMedChem. 2006 Sep;1(9):1007-14. doi: 10.1002/cmdc.200600064. ChemMedChem. 2006. PMID: 16952134

9

Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity.

Krieg AM, Vollmer J. Krieg AM, et al. Among authors: vollmer j. Immunol Rev. 2007 Dec;220:251-69. doi: 10.1111/j.1600-065X.2007.00572.x. Immunol Rev. 2007. PMID: 17979852 Review.

10

A novel class of immune-stimulatory CpG oligodeoxynucleotides unifies high potency in type I interferon induction with preferred structural properties.

Samulowitz U, Weber M, Weeratna R, Uhlmann E, Noll B, Krieg AM, Vollmer J. Samulowitz U, et al. Among authors: vollmer j. Oligonucleotides. 2010 Apr;20(2):93-101. doi: 10.1089/oli.2009.0210. Oligonucleotides. 2010. PMID: 20384481

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

152 results

Search Page

Filters